[1] KOUTROS S, KOGEVINAS M, FRIESEN MC, et al. Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes[J]. Environ Int, 2020, 135: 105346. doi: 10.1016/j.envint.2019.105346
[2] CUMBERBATCH MGK, JUBBER I, BLACK PC, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018[J]. Eur Urol, 2018, 74(6): 784. doi: 10.1016/j.eururo.2018.09.001
[3] BOKARICA P, HRKAC A, GILJA I. Re: J. Alfred Witjes, Thierry Lebret, Eva M. Compérat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer[J]. Eur Urol, 2017, 71: 462.
[4] LUZZAGO S, PALUMBO C, ROSIELLO G, et al. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder[J]. J Surg Oncol, 2019, 120(7): 1266. doi: 10.1002/jso.25717
[5] Bladder cancer: diagnosis and management of bladder cancer: Ⓒ NICE(2015) Bladder cancer: diagnosis and management of bladder cancer[J]. BJU Int, 2017, 120(6): 755.
[6] ZSCHÄBITZ S, NIEGISCH G. Second-line treatment of metastatic urothelial carcinoma: Update immuno-oncology[J]. Urologe A, 2020, 59(7): 804. doi: 10.1007/s00120-020-01236-3
[7] SCHNEIDER AK, CHEVALIER MF, DERRÉ L. The multifaceted immune regulation of bladder cancer[J]. Nat Rev Urol, 2019, 16(10): 613. doi: 10.1038/s41585-019-0226-y
[8] 郭晶晶, 牟迪, 韩颖, 等. Cereblon调节T细胞逆转PD-1抗体治疗肺癌耐药的研究进展[J]. 中国肺癌杂志, 2021, 24(1): 49.
[9] ZHANG W, FENG J, LI Q, et al. The replisome guides nucleosome assembly during DNA replication[J]. Cell Biosci, 2020, 10: 37. doi: 10.1186/s13578-020-00398-z
[10] SHIRAISHI T, SHINTO E, YAMADERA M, et al. Significance of mesothelin expression in preoperative endoscopic biopsy specimens for colorectal cancer prognosis[J]. Oncotarget, 2020, 11(43): 3807. doi: 10.18632/oncotarget.27774
[11] SHIRAISHI T, SHINTO E, MOCHIZUKI S, et al. Mesothelin expression has prognostic value in stage Ⅱ/Ⅲ colorectal cancer[J]. Virchows Arch, 2019, 474(3): 297. doi: 10.1007/s00428-018-02514-4
[12] KIM H, CHUNG Y, PAIK SS, et al. Mesothelin expression and its prognostic role according to microsatellite instability status in colorectal adenocarcinoma[J]. Medicine(Baltimore), 2019, 98(26): e16207.
[13] INAGUMA S, WANG Z, LASOTA J, et al. Comprehensive immunohistochemical study of mesothelin(MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma[J]. Oncotarget, 2017, 8(16): 26744. doi: 10.18632/oncotarget.15814
[14] INOUE S, TSUNODA T, RIKU M, et al. Diffuse mesothelin expression leads to worse prognosis through enhanced cellular proliferation in colorectal cancer[J]. Oncol Lett, 2020, 19(3): 1741.
[15] BARSOUM FS, AWAD AS, HUSSEIN NH, et al. MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer[J]. Pathol Res Pract, 2020, 216(12): 153274. doi: 10.1016/j.prp.2020.153274
[16] THOMAS A, CHEN Y, STEINBERG SM, et al. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis[J]. Oncotarget, 2015, 6(13): 11694. doi: 10.18632/oncotarget.3429
[17] YEN MJ, HSU CY, MAO TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma[J]. Clin Cancer Res, 2006, 12(3 Pt 1): 827.
[18] HMELJAK J, SANCHEZ-VEGA F, HOADLEY KA, et al. Integrative molecular characterization of malignant pleural mesothelioma[J]. Cancer Discov, 2018, 8(12): 1548. doi: 10.1158/2159-8290.CD-18-0804
[19] NICHETTI F, MARRA A, CORTI F, et al. The role of mesothelin as a diagnostic and therapeutic target in pancreatic ductal adenocarcinoma: A comprehensive review[J]. Target Oncol, 2018, 13(3): 333. doi: 10.1007/s11523-018-0567-0
[20] 张军, 董雅璐. 靶向MSLN的CAR-NK-92细胞在胃癌中的抗肿瘤活性研究[J]. 中国医药导报, 2020, 17(19): 11.
[21] ZHANG J, KHANNA S, JIANG Q, et al. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response[J]. Clin Cancer Res, 2017, 23(6): 1564. doi: 10.1158/1078-0432.CCR-16-1667
[22] JIANG H, SONG B, WANG P, et al. Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells[J]. Protein Cell, 2017, 8(12): 926. doi: 10.1007/s13238-017-0472-9
[23] 刘俊, 吴继雄, 张泽华, 等. IL-6、TNF-α与APACHEⅡ评分判断ICU老年重症感染病人预后的价值[J]. 蚌埠医学院学报, 2020, 45(8): 1048.
[24] FU S, LIN J. Blocking interleukin-6 and interleukin-8 signaling inhibits cell viability, colony-forming activity, and cell migration in human triple-negative breast cancer and pancreatic cancer cells[J]. Anticancer Res, 2018, 38(11): 6271. doi: 10.21873/anticanres.12983
[25] HUANG Q, ZHANG Z, LIAO Y, et al. 17β-estradiol upregulates IL-6 expression through the ERβ pathway to promote lung adenocarcinoma progression[J]. J Exp Clin Cancer Res, 2018, 37(1): 133. doi: 10.1186/s13046-018-0804-5
[26] WANG Y, ZONG X, MITRA S, et al. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells[J]. JCI Insight, 2018, 3(23): e122360. doi: 10.1172/jci.insight.122360
[27] 颜春辉, 于燕妮, 郭莉莉. 结直肠癌组织STAT3、Foxp3、IL-6表达与临床病理特征的相关性[J]. 贵州医科大学学报, 2021, 46(1): 85.
[28] SU XH, ZHU YR, HOU YJ, et al. PVT1 induces NSCLC cell migration and invasion by regulating IL-6 via sponging miR-760[J]. Mol Cell Probes, 2020, 54: 101652. doi: 10.1016/j.mcp.2020.101652
[29] KEEGAN A, RICCIUTI B, GARDEN P, et al. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC[J]. J Immunother Cancer, 2020, 8(2): e000678. doi: 10.1136/jitc-2020-000678
[30] XIAO W, WANG L, HOWARD J, et al. TIMP-1-Mediated Chemoresistance via Induction of IL-6 in NSCLC[J]. Cancers(Basel), 2019, 11(8): 1184.
[31] RICE SJ, LIU X, ZHANG J, et al. Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling[J]. Lung Cancer, 2019, 131: 58. doi: 10.1016/j.lungcan.2019.03.014
[32] AN PP, FENG LN, ZHANG XX, et al. Association of interleukin-6 gene polymorphisms with the risk of hepatocellular carcinoma: An up-to-date meta-analysis[J]. Medicine(Baltimore), 2020, 99(50): e23659.
[33] YIN Z, MA T, LIN Y, et al. IL-6/STAT3 pathway intermediates M1/M2 macrophage polarization during the development of hepatocellular carcinoma[J]. J Cell Biochem, 2018, 119(11): 9419. doi: 10.1002/jcb.27259
[34] SREENIVASAN L, WANG H, YAP SQ, et al. Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma[J]. Cell Death Dis, 2020, 11(12): 1035. doi: 10.1038/s41419-020-03241-y
[35] SŁAWIŃSKA M, ZABŁOTNA M, GLEŃ J, et al. STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland[J]. Arch Dermatol Res, 2019, 311(9): 697. doi: 10.1007/s00403-019-01952-7
[36] CHONG PSY, ZHOU J, LIM JSL, et al. IL-6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma[J]. Cancer Res, 2019, 79(18): 4679. doi: 10.1158/0008-5472.CAN-19-0343
[37] SCHMIDT-ARRAS D, ROSE-JOHN S. IL-6 pathway in the liver: From physiopathology to therapy[J]. J Hepatol, 2016, 64(6): 1403. doi: 10.1016/j.jhep.2016.02.004
[38] MA H, YAN D, WANG Y, et al. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma[J]. Cancer Sci, 2020, 111(5): 1862. doi: 10.1111/cas.14416